Profile

Sudan Loganathan is currently a 3rd year PhD Candidate in Neuroscience and Pharmacology conducting his thesis research in the laboratory of Dr. Jailiang Wang in the Department of Neurological Surgery, Vanderbilt University Medical Center.  His research focuses on understanding epigenetic drivers of various types of cancer, and utilizing newly developed target therapy to formulate a treatment option for these cancer types.

Sudan's background has included a strong educational foundation in the Biomedical Sciences.  He completed his B.S. in Biomedical Sciences at Murray State University in 2013, prior to starting his pursuit of a PhD in Neuroscience and Pharmacology.  He is also a member of the Vanderbilt Program of Molecular Medicine, which provides an unique opportunity for researchers to explore the clinical aspect of research, and understand how the discoveries on the lab bench may translate to treatment of patients in the clinic.

While Sudan was pursuing his Bachelor's degree in Biomedical Sciences (2009-2013), Sudan was very active in undergraduate research, which initiated his interest in biomedical research.  He worked under the supervision of Dr. Alexey Arkov to biochemically characterize the function of a novel germline stem cell epigenetic protein.  Subsequently, this led to his graduate career, working to understand the epigenetics of cancer.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. Ma Y, Wang L, Neitzel LR, Loganathan SN, Tang N, Qin L, Crispi EE, Guo Y, Knapp S, Beauchamp RD, Lee E, Wang J (2017) Clin Cancer Res 23(8): 2027-2037
    › Primary publication · 27678457 (PubMed) · PMC5368030 (PubMed Central)
  2. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J (2016) Oncotarget 7(28): 43504-43517
    › Primary publication · 27259270 (PubMed) · PMC5190040 (PubMed Central)
  3. Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. Gong Y, Ma Y, Sinyuk M, Loganathan S, Thompson RC, Sarkaria JN, Chen W, Lathia JD, Mobley BC, Clark SW, Wang J (2016) Neuro Oncol 18(1): 48-57
    › Primary publication · 26136493 (PubMed) · PMC4677408 (PubMed Central)
  4. Glycolytic enzymes localize to ribonucleoprotein granules in Drosophila germ cells, bind Tudor and protect from transposable elements. Gao M, Thomson TC, Creed TM, Tu S, Loganathan SN, Jackson CA, McCluskey P, Lin Y, Collier SE, Weng Z, Lasko P, Ohi MD, Arkov AL (2015) EMBO Rep 16(3): 379-86
    › Primary publication · 25600116 (PubMed) · PMC4364877 (PubMed Central)
  5. Critical functions of RhoB in support of glioblastoma tumorigenesis. Ma Y, Gong Y, Cheng Z, Loganathan S, Kao C, Sarkaria JN, Abel TW, Wang J (2015) Neuro Oncol 17(4): 516-25
    › Primary publication · 25216671 (PubMed) · PMC4483068 (PubMed Central)
  6. An in vivo crosslinking approach to isolate protein complexes from Drosophila embryos. Gao M, McCluskey P, Loganathan SN, Arkov AL (2014) J Vis Exp (86)
    › Primary publication · 24797807 (PubMed) · PMC4174879 (PubMed Central)
  7. Occurrence of bisphenol A in indoor dust from two locations in the eastern United States and implications for human exposures. Loganathan SN, Kannan K (2011) Arch Environ Contam Toxicol 61(1): 68-73
    › Primary publication · 21221962 (PubMed)
  8. Novel role of specific Tudor domains in Tudor-Aubergine protein complex assembly and distribution during Drosophila oogenesis. Creed TM, Loganathan SN, Varonin D, Jackson CA, Arkov AL (2010) Biochem Biophys Res Commun 402(2): 384-9
    › Primary publication · 20946872 (PubMed) · PMC3014500 (PubMed Central)